Journal Mobile Options
Table of Contents
Vol. 61, No. 1, 2001
Issue release date: July 2001
Oncology 2001;61:47–54
(DOI:10.1159/000055352)

Clinical Value of Thymidine Kinase in Patients with Cervical Carcinoma

Fujiwaki R. · Hata K. · Moriyama M. · Iwanari O. · Katabuchi H. · Okamura H. · Miyazaki K.
Departments of Obstetrics and Gynecology,aShimane Medical University, Izumo, bShimane Prefectural Central Hospital, Izumo, and cKumamoto University School of Medicine, Kumamoto, Japan

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Objective: Our purpose was to determine the clinical value of thymidine kinase (TK), which is an important pyrimidine pathway enzyme involved in salvage DNA synthesis, in patients with cervical carcinoma. Methods: We examined TK mRNA expression by reverse transcription polymerase chain reaction in 19 tissue specimens of invasive cervical carcinoma and 9 normal cervices and related it to thymidylate synthase (TS) and thymidine phosphorylase (TP) mRNA expressions. Serum TK level was determined by radioenzymatic assay in 79 patients with invasive cervical carcinoma, 7 patients with microinvasive carcinoma, 21 patients with carcinoma in situ and 32 normal women. Results: TK mRNA expression was upregulated in invasive cervical carcinoma compared with the normal cervix (p < 0.05) and significantly correlated with TS mRNA expression (p < 0.0001) but not with TP mRNA expression. The serum TK level was significantly higher in patients with invasive carcinoma than in normal women and patients with carcinoma in situ (p < 0.01 and p < 0.05). In patients with invasive cervical carcinoma, the serum TK level significantly correlated with TK mRNA expression (p < 0.05), but not with any conventional clinicopathologic factors. High serum TK levels significantly correlated with a poorer survival (p < 0.05), and multivariate analysis showed serum TK level to be an independent prognostic factor (p < 0.05). Conclusion: TK may play an important role in influencing the malignant behavior of cervical carcinoma, and measurement of the serum TK level may be useful in predicting survival in patients with cervical carcinoma.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Taylor AT, Stafford MA, Jones OW: Properties of thymidine kinase partially purified from human fetal and adult tissue. J Biol Chem 1972;247:1930–1935.

    External Resources

  2. Bello LJ: Regulation of thymidine kinase synthesis in human cells. Exp Cell Res 1974;89:263–274.
  3. Desaintes C, Hallez S, Van Alphen P, Burny A: Transcriptional activation of several heterologous promoters by the E6 protein of human papillomavirus type 16. J Virol 1992;66:325–333.

    External Resources

  4. Gronowitz JS, Kallander FR, Diderholm H, Hagberg H, Pettersson U: Application of an in vitro assay for serum thymidine kinase: Results on viral disease and malignancies in humans. Int J Cancer 1984;33:5–12.
  5. Hallek M, Wanders L, Strohmeyer S, Emmerich B: Thymidine kinase: A tumor marker with prognostic value for non-Hodgkin’s lymphoma and a broad range of potential clinical applications. Ann Hematol 1992;65:1–5.
  6. O’Neill KL, Hoper M, Odling-Smee GW: Can thymidine kinase levels in breast tumors predict disease recurrence. J Natl Cancer Inst 1992;84:1825–1828.
  7. Romain S, Martin PM, Klijn JG, Look MP, Guirou O, Foekens JA: DNA-synthesis enzyme activity. A biological tool useful for predicting anti-metabolic drug sensitivity in breast cancer? Int J Cancer 1997;74:156–161.
  8. Romain S, Spyratos F, Descotes F, Daver A, Rostaing-Puissant B, Bougnoux P, Colonna M, Bolla M, Martin PM: Prognostic of DNA-synthesizing enzyme activities (thymidine kinase and thymidylate synthase) in 908 T1-T2, N0-N1, M0 breast cancers: A retrospective multicenter study. Int J cancer 2000;87:860–868.
  9. Robertson JF, O’Neill KL, Thomas MW, McKenna PG, Blamey RW: Thymidine kinase in breast cancer. Br J Cancer 1990;62:663–667.
  10. van der Gaast A, van Putten WL, Oosterom R, Cozijnsen M, Hoekstra R, Splinter TA: Prognostic value of serum thymidine kinase, tissue polypeptide antigen and neuron specific enolase in patients with small cell lung cancer. Br J Cancer 1991;64:369–372.
  11. Lewenhaupt A, Ekman P, Eneroth P, Nilsson B: Tumour markers as prognostic aids in prostatic carcinoma. Br J Urol 1990;66:182–187.
  12. Avall Lundqvist E, Nordstrom L, Sjovall K, Eneroth P: Evaluation of seven different tumour markers for the establishment of tumour marker panels in gynecologic malignancies. Eur J Gynaecol Oncol 1989;10:395–405.

    External Resources

  13. Danenberg PV: Thymidylate synthetase – A target enzyme in cancer chemotherapy. Biochim Biophys Acta 1977;473:73–92.

    External Resources

  14. Brown NS, Bicknell R: Thymidine phosphorylase, 2-deoxy-D-ribose and angiogenesis. Biochem J 1998;334:1–8.
  15. Navalgund LG, Rossana C, Muench AJ, Johnson LF: Cell cycle regulation of thymidylate synthetase gene expression in cultured mouse fibroblasts. J Biol Chem 1980;255:7386–7390.
  16. Kitazono M, Takebayashi Y, Ishitsuka K, Takao S, Tani A, Furukawa T, Miyadera K, Yamada Y, Aikou T, Akiyama S: Prevention of hypoxia-induced apoptosis by the angiogenic factor thymidine phosphorylase. Biochem Biophys Res Commun 1998;253:797–803.
  17. Fujiwaki R, Hata K, Iida K, Maede Y, Koike M, Miyazaki K: Thymidine phosphorylase expression in progression of cervical cancer: Correlation with microvessel count, proliferating cell nuclear antigen, and apoptosis. J Clin Pathol 1999;52:598–603.
  18. Hata K, Takebayashi Y, Iida K, Fujiwaki R, Fukumoto M, Miyazaki K: Expression of thymidine phosphorylase in human cervical cancer. Anticancer Res 1999;19:709–716.

    External Resources

  19. Suzuki M, Tsukagoshi S, Saga Y, Ohwada M, Sato I: Enhanced expression of thymidylate synthase may be of prognostic importance in advanced cervical cancer. Oncology 1999;57:50–54.
  20. Shepherd JH: Cervical and vulva cancer: Changes in FIGO definitions of staging. Br J Obstet Gynaecol 1996;103:405–406.
  21. Poulsen HE, Taylor CW, Sobin LH: Histological Typing of Female Genital Tract. No 13. Geneva, World Health Organization, 1975.
  22. Fujiwaki R, Hata K, Nakayama K, Fukumoto M, Miyazaki K: Thymidylate synthase expression in epithelial ovarian cancer: Relationship with thymidine phosphorylase expression and prognosis. Oncology 2000;68:247–252.
  23. Hata K, Kamikawa T, Arao S, Tashiro H, Katabuchi H, Okamura H, Fujiwaki R, Miyazaki K, Fukumoto M: Expression of the thymidine phosphorylase gene in epithelial ovarian cancer. Br J Cancer 1999;79:1848–1854.
  24. Bristow H, O’Neill KL, Hannigan BM, Mckenna PG: Leakage of thymidine kinase from pro- liferating cells. Biochem Soc Trans 1988;16:55.
  25. Kreis W, Arlin Z, Yagoda A, Leyland-Jones BR, Fiori L: Deoxycytidine and deoxythymidine kinase activities in plasma of mice and patients with neoplastic disease. Cancer Res 1982;42:2514–2517.

    External Resources

  26. Beub U, Allplio B, Kaulen D, Winkelmann W, Arnold W, Pack I: Serum-Thymidine Kinase als Tumor Marker beim Bronchialkarzinom: Stadienabhängigkeit und Verlaufskontrollen. Tumor Diagn Ther 1987;8:69–74.
  27. Gronowitz JS, Kallander CF, Hagberg H, Persson L: Deoxythymidine-kinase in cerebrospinal fluid: A new potential ‘marker’ for brain tumours. Acta Neurochir 1984;73:1–12.
  28. Strang P, Stendahl U, Bergstrom R, Frankendal B, Tribukait B: Prognostic flow cytometric information in cervical squamous cell carcinoma: A multivariate analysis of 307 patients. Gynecol Oncol 1991;43:3–8.
  29. Scanlon KJ, Kashani-Sabet M, Sowers LC: Overexpression of DNA replication and repair enzymes in cisplatin-resistant human colon carcinoma HCT8 cells and circumvention by azidothymidine. Cancer Commun 1989;1:269–275.

    External Resources

  30. al-Nabulsi I, Takamiya Y, Voloshin Y, Dritschilo A, Martuza RL, Jorgensen TJ: Expression of thymidine kinase is essential to low dose radiation resistance of rat glioma cells. Cancer Res 1994;54:5614–5617.
  31. Sekiba K, Yajima A, Tenjin Y, Kurihara S, Akiya K, Okada K, Noda K, Ozaki M, Hasegawa K, Mori T, Jimi S, Nakano H, Yamabe T: Phase II study of 5-FU tablet for cancer of the uterine cervix. Jpn J Cancer Chemother 1987;14:2365–2373.

    External Resources

  32. Kato H, Morioka H, Aramaki S, Tamai K, Torigoe T: Prognostic significance of the tumor antigen TA-4 in squamous cell carcinoma of the uterine cervix. Am J Obstet Gynecol 1983;145:350–354.

    External Resources

  33. Brioschi PA, Bischof P, Delafosse C, Krauer F: Squamous-cell carcinoma antigen (SCC-A) values related to clinical outcome of pre-invasive and invasive cervical carcinoma. Int J Cancer 1991;47:376–379.
  34. te Velde ER, Persijn JP, Ballieux RE, Faber J: Carcinoembryonic antigen serum levels in patients with squamous cell carcinoma of the uterine cervix: Clinical significance. Cancer 1982;49:1866–1873.

    External Resources

  35. Iida K, Fujita K, Hirai H, Goto H, Miyazaki S, Arai Y, Iwaki H, Otake M, Sassa S, Maemura M, Nakayama T, Kudo H, Sakamoto S: Preventive effects of polysaccharides extracted from human tubercle bacilli (specific substance of Maruyama) on colonic carcinogenesis in rats. Cancer Detect Prev 1997;21:476–482.

    External Resources



Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50